These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25886705)

  • 1. PEGylated cationic nanoemulsions can efficiently bind and transfect pIDUA in a mucopolysaccharidosis type I murine model.
    Fraga M; Bruxel F; Diel D; de Carvalho TG; Perez CA; Magalhães-Paniago R; Malachias Â; Oliveira MC; Matte U; Teixeira HF
    J Control Release; 2015 Jul; 209():37-46. PubMed ID: 25886705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors influencing transfection efficiency of pIDUA/nanoemulsion complexes in a mucopolysaccharidosis type I murine model.
    Fraga M; de Carvalho TG; Bidone J; Schuh RS; Matte U; Teixeira HF
    Int J Nanomedicine; 2017; 12():2061-2067. PubMed ID: 28352175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nasal Administration of Cationic Nanoemulsions as Nucleic Acids Delivery Systems Aiming at Mucopolysaccharidosis Type I Gene Therapy.
    Schuh RS; Bidone J; Poletto E; Pinheiro CV; Pasqualim G; de Carvalho TG; Farinon M; da Silva Diel D; Xavier RM; Baldo G; Matte U; Teixeira HF
    Pharm Res; 2018 Sep; 35(11):221. PubMed ID: 30259180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cationic Nanoemulsions as a Gene Delivery System: Proof of Concept in the Mucopolysaccharidosis I Murine Model.
    Fraga M; de Carvalho TG; Diel Dda S; Kretzmann Filho NA; Teixeira HF; Matte U
    J Nanosci Nanotechnol; 2015 Jan; 15(1):810-6. PubMed ID: 26328445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intra-articular nonviral gene therapy in mucopolysaccharidosis I mice.
    Bidone J; Schuh RS; Farinon M; Poletto É; Pasqualim G; de Oliveira PG; Fraga M; Xavier RM; Baldo G; Teixeira HF; Matte U
    Int J Pharm; 2018 Sep; 548(1):151-158. PubMed ID: 29940298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene editing of MPS I human fibroblasts by co-delivery of a CRISPR/Cas9 plasmid and a donor oligonucleotide using nanoemulsions as nonviral carriers.
    Schuh RS; de Carvalho TG; Giugliani R; Matte U; Baldo G; Teixeira HF
    Eur J Pharm Biopharm; 2018 Jan; 122():158-166. PubMed ID: 29122734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene Therapy of Mucopolysaccharidosis Type I Mice: Repeated Administrations and Safety Assessment of pIDUA/Nanoemulsion Complexes.
    Fraga M; Schuh RS; Poletto É; de Carvalho TG; França RT; Pinheiro CV; Baldo G; Giugliani R; Teixeira HF; Matte U
    Curr Gene Ther; 2021; 21(5):464-471. PubMed ID: 33573568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physicochemical properties of cationic nanoemulsions and liposomes obtained by microfluidization complexed with a single plasmid or along with an oligonucleotide: Implications for CRISPR/Cas technology.
    Schuh RS; Poletto É; Fachel FNS; Matte U; Baldo G; Teixeira HF
    J Colloid Interface Sci; 2018 Nov; 530():243-255. PubMed ID: 29982016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physicochemical characterization and gene transfection efficiency of lipid emulsions with various co-emulsifiers.
    Hung CF; Hwang TL; Chang CC; Fang JY
    Int J Pharm; 2005 Jan; 289(1-2):197-208. PubMed ID: 15652212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
    Hadinoto K; Sundaresan A; Cheow WS
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α- L-iduronidase gene-based therapy using the phiC31 system to treat mucopolysaccharidose type I mice.
    Stilhano RS; Martin PK; de Melo SM; Samoto VY; Peres GB; da Silva Michelacci YM; da Silva FH; Pereira VG; D'Almeida V; da Cruz AT; Jasiulionis MG; Han SW
    J Gene Med; 2015; 17(1-2):1-13. PubMed ID: 25597593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo genome editing of mucopolysaccharidosis I mice using the CRISPR/Cas9 system.
    Schuh RS; Poletto É; Pasqualim G; Tavares AMV; Meyer FS; Gonzalez EA; Giugliani R; Matte U; Teixeira HF; Baldo G
    J Control Release; 2018 Oct; 288():23-33. PubMed ID: 30170069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The biological activity of cationic liposomes in drug delivery and toxicity test in animal models.
    Qi P; Cao M; Song L; Chen C; Liu M; Li N; Wu D; Peng J; Hu G; Zhao J
    Environ Toxicol Pharmacol; 2016 Oct; 47():159-164. PubMed ID: 27694054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of the physicochemical and structural properties of pDNA/cationic liposome complexes with their in vitro transfection.
    Balbino TA; Gasperini AA; Oliveira CL; Azzoni AR; Cavalcanti LP; de La Torre LG
    Langmuir; 2012 Aug; 28(31):11535-45. PubMed ID: 22788539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo time-dependent gene expression of cationic lipid-based emulsion as a stable and biocompatible non-viral gene carrier.
    Kwon SM; Nam HY; Nam T; Park K; Lee S; Kim K; Kwon IC; Kim J; Kang D; Park JH; Jeong SY
    J Control Release; 2008 May; 128(1):89-97. PubMed ID: 18384902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of phospholipid composition on cationic emulsions/DNA complexes: physicochemical properties, cytotoxicity, and transfection on Hep G2 cells.
    Fraga M; Bruxel F; Lagranha VL; Teixeira HF; Matte U
    Int J Nanomedicine; 2011; 6():2213-20. PubMed ID: 22114484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure and gene silencing activities of monovalent and pentavalent cationic lipid vectors complexed with siRNA.
    Bouxsein NF; McAllister CS; Ewert KK; Samuel CE; Safinya CR
    Biochemistry; 2007 Apr; 46(16):4785-92. PubMed ID: 17391006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme-responsive destabilization of stabilized plasmid-lipid nanoparticles as an efficient gene delivery.
    Song SJ; Lee S; Lee Y; Choi JS
    Eur J Pharm Sci; 2016 Aug; 91():20-30. PubMed ID: 27240779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of lipid composition in cationic emulsion as in vitro and in vivo transfection agents.
    Kim TW; Chung H; Kwon IC; Sung HC; Jeong SY
    Pharm Res; 2001 Jan; 18(1):54-60. PubMed ID: 11336353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of PEGylated nanoemulsions for improved pharmacokinetics of BCS class II compounds.
    Devalapally H; Zhou F; McDade J; Goloverda G; Owen A; Hidalgo IJ; Silchenko S
    Drug Deliv; 2015; 22(4):467-74. PubMed ID: 24344786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.